BlackRock’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-495,800
Closed -$58.7M 5660
2021
Q1
$58.7M Buy
495,800
+73,280
+17% +$8.67M ﹤0.01% 2520
2020
Q4
$49.9M Sell
422,520
-48,431
-10% -$5.62M ﹤0.01% 2474
2020
Q3
$52.3M Buy
470,951
+23,355
+5% +$2.51M ﹤0.01% 2274
2020
Q2
$45.7M Buy
447,596
+62,703
+16% +$6.71M ﹤0.01% 2302
2020
Q1
$41.5M Sell
384,893
-1,538
-0.4% -$177K ﹤0.01% 2174
2019
Q4
$45M Sell
386,431
-34,624
-8% -$4.01M ﹤0.01% 2433
2019
Q3
$48.2M Buy
421,055
+28,478
+7% +$2.83M ﹤0.01% 2308
2019
Q2
$37.4M Sell
392,577
-25,424
-6% -$2.39M ﹤0.01% 2493
2019
Q1
$38.1M Sell
418,001
-26,401
-6% -$2.16M ﹤0.01% 2414
2018
Q4
$33.7M Buy
444,402
+6,347
+1% +$467K ﹤0.01% 2451
2018
Q3
$35M Sell
438,055
-80,626
-16% -$7.51M ﹤0.01% 2572
2018
Q2
$51.5M Sell
518,681
-407,731
-44% -$35.2M ﹤0.01% 2341
2018
Q1
$75M Buy
926,412
+247,555
+36% +$20M ﹤0.01% 2027
2017
Q4
$53.5M Sell
678,857
-38,693
-5% -$3.22M ﹤0.01% 2249
2017
Q3
$66.2M Sell
717,550
-701,375
-49% -$67.4M ﹤0.01% 2097
2017
Q2
$160M Sell
1,418,925
-89,171
-6% -$9.97M 0.01% 1458
2017
Q1
$151M Buy
1,508,096
+1,318,183
+694% +$141M 0.01% 1498
2016
Q4
$20.4M Buy
189,913
+78,375
+70% +$9.16M 0.03% 552
2016
Q3
$13.9M Buy
111,538
+4,999
+5% +$590K 0.02% 642
2016
Q2
$11.3M Sell
106,539
-15,416
-13% -$1.79M 0.02% 666
2016
Q1
$14M Buy
121,955
+2,717
+2% +$319K 0.02% 598
2015
Q4
$17M Buy
119,238
+13,727
+13% +$1.58M 0.02% 571
2015
Q3
$9.48M Sell
105,511
-54,533
-34% -$5.76M 0.01% 646
2015
Q2
$18.4M Buy
+160,044
New +$16.8M 0.03% 543

BlackRock's CBPO Position: Q2 2021 in Review

BlackRock sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2021, closing a stake of 495,800 shares — an estimated $58.7M sold.

BlackRock first reported a position in CBPO in Q2 2015 and held it in 24 quarters. The position peaked at $160M in Q2 2017. 0 funds tracked by Wall St. Rank hold CBPO as of Q2 2021.

  • BlackRock reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2021 after selling out during the quarter.
  • BlackRock sold 495,800 China Biologic Products Holdings, Inc. shares in Q2 2021, an estimated $58.7M.
  • BlackRock first reported a position in China Biologic Products Holdings, Inc. in Q2 2015 and held it in 24 quarters.
  • BlackRock's China Biologic Products Holdings, Inc. position peaked at $160M in Q2 2017.
  • 0 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2021.

Based on BlackRock's 13F filing for Q2 2021, filed 11 Aug 2021.